RAPT Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2015-03-04
- Employees
- 131
- Market Cap
- $80.9M
- Website
- http://rapt.com
- Introduction
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company was founded in 2015 and is headquartered in South San Francisco, CA.
Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)β’ Click on a phase to view related trials
Study of RPT193 in Healthy Adult Male Subjects
- Conditions
- Healthy Male Subjects
- Interventions
- Drug: 14C RPT193
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT06087978
- Locations
- πΊπΈ
Celerion, Lincoln, Nebraska, United States
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05935332
- Locations
- πΊπΈ
Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States
πΊπΈBensch Clinical Research LLC, Stockton, California, United States
πΊπΈAllianz Research Institute, Westminster, California, United States
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT05399368
- Locations
- πΊπΈ
Cahaba Dermatology and Skin Health Center, Birmingham, Alabama, United States
πΊπΈPerseverance Research Center, Scottsdale, Arizona, United States
πΊπΈArkansas Research Trials, LLC, North Little Rock, Arkansas, United States
FLX475 in Combination With Ipilimumab in Advanced Melanoma
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04894994
- Locations
- πΊπΈ
University of California, Los Angeles, Los Angeles, California, United States
πΊπΈMoffitt Cancer Center, Tampa, Florida, United States
πΊπΈWashington University School of Medicine St. Louis, Saint Louis, Missouri, United States
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04271514
- Locations
- πΊπΈ
Pinnacle Research Group, LLC, Anniston, Alabama, United States
πΊπΈPerseverance Research Center LLC, Scottsdale, Arizona, United States
πΊπΈUniversity Clinical Trials, Inc, San Diego, California, United States
- Prev
- 1
- 2
- Next